Trial · NCT00536263
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | 39 | Participants | ||
| Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss | PEG 1.5 mcg/kg QW * 24 Weeks | 40 | Participants | ||
| Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss | PEG 1.5 mcg/kg QW * 48 Weeks | 70 | Participants | ||
| Number of Participants With HBeAg Loss | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | 31 | Participants | ||
| Number of Participants With HBeAg Loss | PEG 1.5 mcg/kg QW * 24 Weeks | 28 | Participants | ||
| Number of Participants With HBeAg Loss | PEG 1.5 mcg/kg QW * 48 Weeks | 43 | Participants | ||
| HBe Seroconversion | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | EOT | 31 | Participants | |
| HBe Seroconversion | PEG 1.5 mcg/kg QW * 24 Weeks | EOT | 27 | Participants | |
| HBe Seroconversion | PEG 1.5 mcg/kg QW * 48 Weeks | EOT | 40 | Participants | |
| HBe Seroconversion | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | 24 weeks after EOT | 38 | Participants | |
| HBe Seroconversion | PEG 1.5 mcg/kg QW * 24 Weeks | 24 weeks after EOT | 36 | Participants | |
| HBe Seroconversion | PEG 1.5 mcg/kg QW * 48 Weeks | 24 weeks after EOT | 67 | Participants | |
| Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | EOT | 46 | Participants | |
| Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL | PEG 1.5 mcg/kg QW * 24 Weeks | EOT | 61 | Participants | |
| Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL | PEG 1.5 mcg/kg QW * 48 Weeks | EOT | 76 | Participants | |
| Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | 24 weeks after EOT | 44 | Participants | |
| Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL | PEG 1.5 mcg/kg QW * 24 Weeks | 24 weeks after EOT | 47 | Participants | |
| Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL | PEG 1.5 mcg/kg QW * 48 Weeks | 24 weeks after EOT | 75 | Participants | |
| Number of Participants With HBV-DNA < 200 IU/mL | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | EOT | 10 | Participants | |
| Number of Participants With HBV-DNA < 200 IU/mL | PEG 1.5 mcg/kg QW * 24 Weeks | EOT | 14 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00536263/results